Atorvastatin
Atorvastatin has been studied in 368 papers since 2001: 75 trials and 100 observational studies in people, 85 in animals, 24 in cells, 48 reviews; 184 in the past year. It is an approved medicine. The newest paper, Nov 17, 2026: “Comparative Effects of Atorvastatin and Pravastatin on Endothelial Viability and DRP1-Associated Signaling Following Irradiation”.
InterventionStatinsApproved 1996
368 papers study it40 more mention it444 findingsUpdated
46 new papers in 30 daysSee all 404 papers on atorvastatin
At a glance
Atorvastatin improves cognition in mice across independent labs, although a mouse finding shows no clear effect; a human trial reports increased telomerase activity in people with hypercholesterolemia. Some trials concern aging; across all uses, some ended over a year ago without posted results or a citing paper. Some papers declare company ties, and some trials have developer sponsors.
444 findings in 192 papers from 2001 to 2026, 30 of them since May 2026
Independent labs found the same change in cells, mice and people. 148 independent labs in 40 countries; 530 trials, 93 about aging, 250 with no results posted.
“a primary cardiovascular event had occurred in 297 participants (10.9 events per 1000 person-years) in the atorvastatin group and in 412 participants (15.5 events per 1000 person-years) in the placebo group”
21 of its findings point the other way.
- 148 independent labs in 40 countries
- 21 findings against
- 530 trials, 93 about aging, 250 with no results posted
- Funders: National Natural Science Foundation of China and others
- 25 of 427 findings with company ties
- 72 of 530 trials sponsored by its developers
- Human trial74
- Humans99
- Animals83
- Model organisms1
- Cells24
- In silico8
Studies in people
See all 44 studies of atorvastatin in people44 studies gave atorvastatin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on cisplatin-induced ototoxicity41.38% of the case group versus 44.4% of the control group experienced ototoxicity | Randomized trial | 56 peoplePatients with solid tumors receiving cisplatin chemotherapy | Drug design, development and therapy, Nov 7, 2026 |
up: Increases proteomic response140 significant proteins in G1 versus 68 in G2+G3; FDR q<0.05 up: Increases CALCA/CGRPFDR q=0.044 | Randomized trial | 133 peopleConfirmed statin myalgia compared with nocebo and tolerant controls | AHA Scientific Sessions 2026 abstract, Nov 2, 2026 |
down: Lowers the risk of cardiovascular diseaseHR 0.70, 95% CI 0.61–0.82, P<0.001 no change: Has no effect on disability-free survivalHR 0.94, 95% CI 0.84–1.05, P = 0.25 | Randomized trial5.9 years | 9,971 peopleBoth74.7±4.5 yearsOlder adults | The New England journal of medicine, Aug 29, 2026 |
down: Decreases endocan down: Decreases endoglin | Treated cohortmedian 12 (IQR 8–12) weeks | 128 peoplewomenmedian age 60 years (IQR 56–64 years)Postmenopausal women aged up to 70 years | Biomedicines, Aug 27, 2026 |
no change: Has no effect on frailty status down: Decreases body weight no change: Has no effect on myostatin | Randomized trial12 weeks | Patient cohorts | Narra X, Jul 13, 2026 |
What did studies of atorvastatin find?
283Studies of atorvastatin measured 283 outcomes; the most studied are inflammation (16 studies), cognitive function (10) and LDL cholesterol (9).
Inflammation
downin humans6downin mice4downin rats4downin mouse cells1+1
16 studies
Inflammation
downin humans6downin mice4downin rats4downin mouse cells1+1
Atorvastatin inhibits inflammation in humans (decompensated liver cirrhosis).
“Inflammatory biomarkers demonstrated a marked response to atorvastatin therapy.”
Human trialdecompensated liver cirrhosissix monthsn = 110
Scientific reports
Atorvastatin inhibits inflammation in humans (decompensated cirrhosis) (P < 0.05).
“These clinical improvements were mirrored by significant reductions in MDA, NF-κB, LPS, and zonulin levels (P < 0.05)”
Human trialdecompensated cirrhosis20 mg/daysix monthsn = 100
Scientific reports
Atorvastatin decreases inflammation in humans (combined with polyene phosphatidylcholine in MAFLD patients) (all P < 0.05).
“inflammatory factors and liver injury index transforming growth factor-β (TGF-β) and nuclear transcription factor-κB (NF-κB) levels were significantly improved (all P < 0.05)”
Human trialcombined with polyene phosphatidylcholine in MAFLD patientssix monthsn = 92
Pakistan journal of pharmaceutical sciences
Atorvastatin decreases inflammation in humans (versus ezetimibe, on background PCSK9 inhibitor therapy).
“statins provide greater improvements to EC health and anti-inflammatory effects, supporting their benefits beyond LDL-C reduction.”
Human trialversus ezetimibe, on background PCSK9 inhibitor therapyendothelial cells1 month
AHA Scientific Sessions 2025 abstract
Atorvastatin decreases inflammation in humans (hypertension).
“serum inflammatory markers, including TNF-α, hs-CRP, and IL-6, were significantly lower in the experimental group than in the control group (all P < 0.05).”
Human trialhypertension12 weeksn = 68
American journal of translational research
Atorvastatin decreases inflammation.
“After treatment, reduced levels of IL-6, TNF-α, and hs-CRP were noted in the observation group versus those in the control group (all p < 0.05).”
Human trial12 weeksn = 86
Diagnostic pathology
Atorvastatin decreases inflammation in humans.
“the available evidence supports the combined lipid-lowering and anti-inflammatory effects of atorvastatin across diverse patient populations”
Review
Frontiers in pharmacology
Atorvastatin decreases inflammation in mice (female AS mouse models).
“reduces inflammatory signaling, and enhances plaque stabilization in female AS mouse models.”
Animalsfemale AS mouse modelsfemales
Nature communications
Atorvastatin decreases inflammation in rats (zoledronic acid-induced MRONJ).
“It also reduced inflammation”
Animalszoledronic acid-induced MRONJHPMC and graphene oxide hydrogel loaded with ATVjaw1.2%three weeksfemales
Tissue & cell
Atorvastatin inhibits inflammation in mice (myocardial infarction).
“decreased levels of tumor necrosis factor-α, interleukin-6, and malondialdehyde”
Animalsmyocardial infarction
Nanomedicine (London, England)
All 17Fewer
Cognitive function
upin mice4upin rats4upin humans1no changein humans1+1
10 studies
Cognitive function
upin mice4upin rats4upin humans1no changein humans1+1
Atorvastatin improves cognitive function in humans (β = 0.980, P < 0.001).
“atorvastatin was an independent protective factor for cognitive recovery (β = 0.980, P < 0.001).”
Human trial20 mg nightly6 monthsn = 67
Frontiers in pharmacology
Atorvastatin showed no clear effect on cognitive function in humans (0.1 units (95% CI, -0.3 to 0.03)).
“with no significant group differences (0.1 units; 95% CI, -0.3 to 0.03; P = .12)”
Human trialwithout dementia and with hypertension, family history of dementia, and/or self-reported subjective cognitive decline24 monthsn = 480
JAMA neurology
Atorvastatin improves cognitive function in TNP rats.
“improved learning ability, preserved myelin structure, and restored MBP levels”
Animalsin TNP rats10 mg/kg/day
Neuroscience research
Atorvastatin improves cognitive function in rats.
“long-term atorvastatin intervention ameliorates cognitive decline in naturally aged rats”
Animalsbrainlong-term
Cell death discovery
Atorvastatin improves cognitive function in rats (Aβ1−42-induced Alzheimer's disease model).
“We confirmed that ATOR administration significantly attenuates the Aβ1−42-induced cognitive decline”
AnimalsAβ1−42-induced Alzheimer's disease modelbrainmales
Molecular neurobiology
Atorvastatin improves cognitive function in ApoE-/- mice.
“Collectively, Atorvastatin mitigated memory deficits and brain monocyte infiltration in ApoE-/- mice.”
Animalsin ApoE-/- miceoral10 mg/kg/day
Aging
Atorvastatin improves cognitive function in rats (AlCl3-induced model; alone and combined with magnesium l-threonate; radial arm maze).
“At the end of the fourth week, administration of atorvastatin and atorvastatin with magnesium L-threonate resulted in a decreased average time taken to reach the correct arm”
AnimalsAlCl3-induced model; alone and combined with magnesium l-threonate; radial arm mazefemalesn = 30
Cureus
Atorvastatin improves cognitive function in hyperhomocysteinemic mice, tested by novel object recognition.
“atorvastatin treatment in HHcy mice led to improved cognition on the novel object recognition task”
Animalsin hyperhomocysteinemic mice, tested by novel object recognition14 weeks
Journal of neuroinflammation
Atorvastatin showed no clear effect on cognitive function in mice (high-fat diet-induced cognition impairment).
“However, these effects were not observed in the high-dose of Ator.”
Animalshigh-fat diet-induced cognition impairment80 mg7 monthsmales
Neurochemical research
Atorvastatin improves cognitive function in mice (high-fat diet-induced cognition impairment).
“Our results showed that moderate- and low-dose of Ator can significantly attenuate cognition impairment induced by HFD”
Animalshigh-fat diet-induced cognition impairment20 or 40 mg7 monthsmales
Neurochemical research
All 11Fewer
LDL cholesterol
downin humans9−41%
9 studies
LDL cholesterol
downin humans9−41%
Atorvastatin decreases LDL cholesterol in humans (acute myocardial infarction) (43 ± 16 mg/dL vs 48 ± 14 mg/dL, p = 0.046).
“Group A had lower mean LDL-C (43 ± 16 mg/dL vs 48 ± 14 mg/dL; p = 0.046)”
Human trialacute myocardial infarctionatorvastatin 80 mg or rosuvastatin 40 mg plus ezetimibe 10 mg vs atorvastatin 40 mg or rosuvastatin 20 mg plus ezetimibe 10 mg30 daysn = 220
International journal of cardiology
Atorvastatin decreases LDL cholesterol in humans (compared with pravastatin 40 mg/day) (-53% vs -28% median percent change (pravastatin)).
“The median percent lowering (interquartile range) in LDL-C was significantly greater with ATV than PRV [-53 (-69 to 20)% vs -28 (-55 to 74)%, p < 0.001]”
Human trialcompared with pravastatin 40 mg/day80 mg/day12 monthsfemalesn = 420
Atherosclerosis
Atorvastatin decreases LDL cholesterol in humans (-40.0 mg/dL (95%CI -69.910 to -10.1)).
“Atorvastatin reduced LDL-c by 40.0 mg/dL (95%CI: -69.910--10.1; p = 0.010)”
Human trial80 mgfemales
Antioxidants (Basel, Switzerland)
Atorvastatin decreases LDL cholesterol in humans.
“a fast decline of LDL-cholesterol, after intake of atorvastatin”
Human trial
Case of hepatotoxicity of atorvastatin: the search for a possible etiology
Tijdschrift voor gerontologie en geriatrie
Atorvastatin decreases LDL cholesterol in humans.
“Atorvastatin administration resulted in a significant decrease in blood levels of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, vitamin E, and CoQ10 (P < .05)”
Human trial10 mg/d5 monthsn = 19
Nutrition research (New York, N.Y.)
Atorvastatin decreases LDL cholesterol in humans (heterozygous familial hypercholesterolemia) (-40.7%).
“Pitavastatin and atorvastatin caused significant and almost comparable reductions in serum levels of total cholesterol (-35.4 vs. -33.8%), low-density lipoprotein cholesterol (-42.8 vs. -40.7%)”
Human trialheterozygous familial hypercholesterolemia20 mgn = 19
Clinical pharmacology and therapeutics
Atorvastatin decreases LDL cholesterol in humans (CoQ10 and placebo arms) (43% decrease in CoQ10 group; 49% decrease in placebo group).
“Serum LDL-C levels in the CoQ10 group decreased by 43%, while in the placebo group by 49%.”
Human trialCoQ10 and placebo arms10mg/day16 weeks
Atherosclerosis
Atorvastatin decreases LDL cholesterol in humans (chronic heart failure) (p<0.001).
“Atorvastatin treatment lowered triglycerides, LDL-cholesterol and coenzyme Q(10) levels (all p<0.001)”
Human trialchronic heart failure40 mg6 weeksn = 24
Atherosclerosis
Atorvastatin decreases LDL cholesterol in humans.
“Atorvastatin exhibits several notable features: a titratable dosing strategy that spans all risk categories, robust LDL-C lowering”
Review
Frontiers in pharmacology
Oxidative stress and ROS signaling
downin mice5downin rats2upin C. albicans cells1upin O. niloticus1
9 studies
Oxidative stress and ROS signaling
downin mice5downin rats2upin C. albicans cells1upin O. niloticus1
Atorvastatin induces oxidative stress and ROS signaling in O. niloticus.
“Lipid peroxidation increased only at 0.2 and 0.5 mg/kg of ATV, suggesting oxidative damage at these concentrations.”
Animals0.2 and 0.5 mg/kg45 days
Research SquarePreprint
Atorvastatin increases oxidative stress and ROS signaling in C. albicans cells (Strain MTCC 854) (18-fold increase).
“ROS generation assay revealed an 18-fold increase in oxidative stress with Atorvastatin, while Simvastatin showed only a 4-fold increase.”
CellsStrain MTCC 854
Future microbiology
Atorvastatin inhibits oxidative stress and ROS signaling in mice (myocardial infarction).
“increased the enzyme activity of superoxide dismutase”
Animalsmyocardial infarction
Nanomedicine (London, England)
Atorvastatin decreases oxidative stress and ROS signaling in mice (PM2.5 exposure).
“Both drugs ameliorated reactive oxygen species (ROS) formation”
AnimalsPM2.5 exposurevasculature20 mg/kg/d3 daysmales
Antioxidants (Basel, Switzerland)
Atorvastatin decreases oxidative stress and ROS signaling in rats (aged rats).
“as evidenced by increased levels of Nrf-2, GSH, and SOD, along with a reduction in MDA levels”
Animalsaged ratscerebral cortex20 mg/kg30 days
Tissue & cell
Atorvastatin decreases oxidative stress and ROS signaling in rats (AlCl3-induced model; alone and combined with magnesium l-threonate; brain).
“and suppressed oxidative stress, as indicated by a decrease in nitric oxide (NO) levels and an increase in superoxide dismutase (SOD) and catalase levels.”
AnimalsAlCl3-induced model; alone and combined with magnesium l-threonate; brainbrainfemalesn = 30
Cureus
Atorvastatin prevents oxidative stress and ROS signaling in mice (age-related hearing loss).
“These processes of ARHL were significantly prevented with administration of AS.”
Animalsage-related hearing loss6 consecutive months
Effect of statin on age-related hearing loss via drug repurposing
Biochimica et biophysica acta. Molecular cell research
Atorvastatin decreases oxidative stress and ROS signaling in mice (chronic intermittent hypoxia).
“Atorvastatin significantly reversed those effects (p < 0.05).”
Animalschronic intermittent hypoxiacardiac tissue5 mg/kg6 weeks
Aging
Atorvastatin decreases oxidative stress and ROS signaling in mice (high-fat diet-induced cognition impairment).
“MDA was notably decreased, whereas the activity of SOD, CAT, and GSH-Px was increased.”
Animalshigh-fat diet-induced cognition impairment20 or 40 mg7 monthsmales
Neurochemical research
Apoptosis
upin human cells2downin mice2downin rats2no changein mice1+1
8 studies
Apoptosis
upin human cells2downin mice2downin rats2no changein mice1+1
Atorvastatin decreases apoptosis in mice (doxorubicin cardiotoxicity).
“In a murine model of DOX cardiotoxicity, atorvastatin preserved left ventricular systolic function, reduced myocardial apoptosis and fibrosis”
Animalsdoxorubicin cardiotoxicitymyocardium
Atorvastatin protects cardiomyocytes from doxorubicin toxicity by modulating YAP/TAZ signaling
BMB reports
Atorvastatin inhibits apoptosis in mice (myocardial infarction).
“Ato@DSPE-PEG-CHP reduced infarct size, cell necrosis, inflammation, fibrosis, and apoptosis”
Animalsmyocardial infarction
Nanomedicine (London, England)
Atorvastatin induces apoptosis in lipopolysaccharide-stimulated HT-29 and Caco-2 cells.
“Both pathways converge upon activation of executioner caspase-3 and an increase in Annexin V-defined apoptotic fractions”
Cellsin lipopolysaccharide-stimulated HT-29 and Caco-2 cells
International journal of molecular sciences
Atorvastatin induces apoptosis in two PCa cell lines.
“Results of cell experiments also demonstrated that statins use could promote apoptosis of PCa cells.”
Cellsin two PCa cell lines
Frontiers in pharmacology
Atorvastatin decreases apoptosis in rats (aged rats).
“apoptosis was mitigated through the downregulation of Caspase-3”
Animalsaged ratscerebral cortex20 mg/kg30 days
Tissue & cell
Atorvastatin decreases apoptosis in scar region of RE-AMI.
“The scar region of RE-AMI of animals treated with IV-atorva at index event showed reduced cardiac inflammatory infiltrate, apoptosis and senescence activation”
Animalsin scar region of RE-AMImyocardium
Cardiovascular research
Atorvastatin inhibits apoptosis in MI/R and H/R model.
“atorvastatin treatment attenuated MI/R and H/R mediated inflammatory and heart injury markers, cell apoptosis and cell death”
Animalsin MI/R and H/R model
Journal of drug targeting
Atorvastatin showed no clear effect on apoptosis in mice (chronic intermittent hypoxia).
“Atorvastatin had no effect on those changes (p > 0.05).”
Animalschronic intermittent hypoxiacardiac tissue5 mg/kg6 weeks
Aging
Cellular senescence
downin human cells3upin mice1downin pigs1downin rats1
6 studies
Cellular senescence
downin human cells3upin mice1downin pigs1downin rats1
Atorvastatin decreases cellular senescence in scar region of RE-AMI.
“The scar region of RE-AMI of animals treated with IV-atorva at index event showed reduced cardiac inflammatory infiltrate, apoptosis and senescence activation”
Animalsin scar region of RE-AMImyocardium
Cardiovascular research
Atorvastatin inhibits cellular senescence in human cells (caused by oxidative stress and 5-Fu).
“Atorvastatincalcium (Ator) alleviated cellular senescence in human intestinal epithelial cells (HUVECs) and human umbilical vein endothelial cells (HIECs) caused by oxidative stress and 5-Fu.”
Cellscaused by oxidative stress and 5-Fu
International immunopharmacology
Atorvastatin induces cellular senescence in mice.
“as well as increased accumulation of the senescence-associated β-galactosidase (SA-β-gal) stain in adipose tissues”
Animalsadipose tissue
Nutrients
Atorvastatin decreases cellular senescence in human cells (IH-mediated senescence-like phenotype in preadipocytes).
“Intervention with aspirin, atorvastatin or renin-angiotensin system (RAS) inhibitors effectively attenuated IH-mediated senescence-like phenotype.”
CellsIH-mediated senescence-like phenotype in preadipocyteswhite preadipocytes
Chronic Intermittent Hypoxia Triggers a Senescence-like Phenotype in Human White Preadipocytes
Scientific reports
Atorvastatin decreases cellular senescence in human cells (Ang II-induced dysfunction).
“endothelial senescence, which was delayed by Ator”
CellsAng II-induced dysfunction
Experimental and therapeutic medicine
Atorvastatin decreases cellular senescence in rats (high-fat diet-induced hyperlipidemia).
“these phenomena were reversed by atorvastatin”
Animalshigh-fat diet-induced hyperlipidemia
Mechanisms of ageing and development
Coenzyme Q10
downin humans4no changein humans1
5 studies
Coenzyme Q10
downin humans4no changein humans1
Atorvastatin decreases coenzyme Q10 in humans.
“Atorvastatin administration resulted in a significant decrease in blood levels of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, vitamin E, and CoQ10 (P < .05)”
Human trial10 mg/d5 monthsn = 19
Nutrition research (New York, N.Y.)
Atorvastatin decreases coenzyme Q10 in humans (-26.1%, P=0.0007).
“plasma levels of CoQ10 were reduced by atorvastatin (-26.1%, P=0.0007)”
Human trial20 mgn = 19
Clinical pharmacology and therapeutics
Atorvastatin decreases coenzyme Q10 in humans after 3 months of atorvastatin therapy (0.43 +/- 0.23 to 0.16 +/- 0.10 microg/mL).
“coenzyme Q10 (0.43 +/- 0.23 to 0.16 +/- 0.10 microg/mL) were all significantly reduced (all p<0.001)”
Human trialafter 3 months of atorvastatin therapy10 mg/day3 monthsn = 26
BioFactors (Oxford, England)
Atorvastatin decreases coenzyme Q10 in humans (chronic heart failure) (p<0.001).
“Atorvastatin treatment lowered triglycerides, LDL-cholesterol and coenzyme Q(10) levels (all p<0.001)”
Human trialchronic heart failure40 mg6 weeksn = 24
Atherosclerosis
Atorvastatin showed no clear effect on coenzyme Q10 in humans (0.65 +/- 0.22 vs 0.6 +/- 0.12 microg/mL, P >.05).
“There was no difference in CoQ10 levels from baseline to post-drug therapy for either P or A”
Human trial10 mg4 weeks
The effect of pravastatin and atorvastatin on coenzyme Q10
American heart journal
Total cholesterol
downin humans2no changein humans1no changein O. cuniculus1
4 studies
Total cholesterol
downin humans2no changein humans1no changein O. cuniculus1
Atorvastatin showed no clear effect on total cholesterol in humans (compared with placebo, fully adjusted model).
“atorvastatin did not improve frailty status, frailty-related components, total cholesterol, or serum myostatin levels compared with placebo in PLHIV receiving ART”
Human trialcompared with placebo, fully adjusted model40 mg once daily12 weeks
Narra X
Atorvastatin decreases total cholesterol in humans (early menopausal women with hypercholesterolemia; compared to baseline).
“both Xuezhikang and atorvastatin significantly reduced the levels of total cholesterol, triglycerides, low density cholesterol compared to baseline (all P<0.01).”
Human trialearly menopausal women with hypercholesterolemia; compared to baselineserum10 mg/d8 weeksfemales
Chinese journal of integrative medicine
Atorvastatin decreases total cholesterol in humans (decreased significantly).
“Serum total cholesterol and LDL-cholesterol levels decreased significantly.”
Human trial10 mg/day8 weeksn = 14
Journal of atherosclerosis and thrombosis
Atorvastatin showed no clear effect on total cholesterol in WHHL rabbits.
“No effect on total cholesterol, triglycerides, HDL or LDL was observed.”
Animalsin WHHL rabbits2.5 mg/kg/daymalesn = 34
Atherosclerosis
Hematoma volume
downin humans2no changein humans1downin rats1
4 studies
Hematoma volume
downin humans2no changein humans1downin rats1
Atorvastatin decreases hematoma volume in humans.
“Atorvastatin significantly reduced hematoma volume and elevated MoCA scores at 1, 3 and 6 months”
Human trial20 mg nightly6 monthsn = 67
Frontiers in pharmacology
Atorvastatin showed no clear effect on hematoma volume in humans (postoperative chronic subdural hematoma) (p=0.979).
“The hematoma volume was similar between the 2 groups (p=0.979).”
Human trialpostoperative chronic subdural hematomaoralat least 1 weekn = 49
Effects of postoperative atorvastatin use in elderly patients with chronic subdural hematoma
European review for medical and pharmacological sciences
Atorvastatin decreases hematoma volume in humans (Chronic subdural hematoma; uncontrolled before-and-after comparison) (48.70±20.38 ml to 16.64±14.28 ml).
“the reduction in hematoma volume from 48.70±20.38 ml to 16.64±14.28 ml (paired-sample t-test, p<0.01) within the first month of the treatment.”
Human trialChronic subdural hematoma; uncontrolled before-and-after comparison20 mg/day1 monthn = 23
Journal of the neurological sciences
Atorvastatin decreases hematoma volume in rats with CSDH, compared with saline (decreased on day 14 and day 21 (P<0.05)).
“atorvastatin treatment accelerated the absorption of CSDH as indicated by decreased hematoma volume in T2WI MRI data on 14th and 21st day after CSDH”
Animalsin rats with CSDH, compared with salineday 14 and day 21
Role of Regulatory T cells in Atorvastatin Induced Absorption of Chronic Subdural Hematoma in Rats
Aging and disease
Low-density lipoprotein cholesterol
downin humans4−47%
4 studies
Low-density lipoprotein cholesterol
downin humans4−47%
Atorvastatin decreases low-density lipoprotein cholesterol in humans (overweight and obese middle-aged and older adults) (-47%).
“the ATOR group experienced a 47% reduction in low-density lipoprotein cholesterol (149+/-6 to 80+/-8 mg/dL)”
Human trialoverweight and obese middle-aged and older adults80 mg/d12 weeksn = 16
Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults
Hypertension (Dallas, Tex. : 1979)
Atorvastatin decreases low-density lipoprotein cholesterol in humans after 3 months of atorvastatin therapy.
“coenzyme Q10 (0.43 +/- 0.23 to 0.16 +/- 0.10 microg/mL) were all significantly reduced (all p<0.001)”
Human trialafter 3 months of atorvastatin therapy10 mg/day3 monthsn = 26
BioFactors (Oxford, England)
Atorvastatin decreases low-density lipoprotein cholesterol in humans (102 +/- 21 vs 52 +/- 14 mg/dL, P <.01).
“There was a significant difference in low-density lipoprotein (LDL) levels from baseline to post-drug therapy for both P and A”
Human trial10 mg4 weeks
The effect of pravastatin and atorvastatin on coenzyme Q10
American heart journal
Atorvastatin decreases low-density lipoprotein cholesterol in patients with lung diseases (WMD -21.48 mg/dL, 95% CI -30.82 to -12.14).
“LDL cholesterol (WMD: - 21.48 mg/dL; 95% CI - 30.82 to - 12.14)”
Reviewin patients with lung diseasesn = 1,344
European journal of medical research
C-reactive protein
downin humans4−6% decrease
4 studies
C-reactive protein
downin humans4−6% decrease
Atorvastatin decreases C-reactive protein in humans (on background PCSK9 inhibitor therapy) (6% decrease).
“After 1 month of LLT, LDL-C and hsCRP decreased by 80% and 6%, respectively, in the statin group (P<0.05 for each).”
Human trialon background PCSK9 inhibitor therapy80 mg1 month
AHA Scientific Sessions 2025 abstract
Atorvastatin decreases C-reactive protein in humans (very elderly patients with type 2 diabetes).
“Atorvastatin significantly reduced homocysteine and C-reactive protein”
Human trialvery elderly patients with type 2 diabetes
Journal of diabetes investigation
Atorvastatin decreases C-reactive protein in humans (atherosclerotic subjects, 12-week treatment).
“The TBR as well as high-sensitivity C-reactive protein (hsCRP), E-selectin, MMP-9, monocyte chemotactic protein 1, FABP4 and follistatin values were reduced significantly after the 12-week atorvastatin treatment.”
Human trialatherosclerotic subjects, 12-week treatment40 mg/day12 weeksn = 43
European journal of nuclear medicine and molecular imaging
Atorvastatin decreases C-reactive protein in humans (overweight and obese middle-aged and older adults) (-42%).
“a 42% reduction in high-sensitivity C-reactive protein (3.6+/-0.8 to 2.1+/-0.5 mg/L; both P<0.05).”
Human trialoverweight and obese middle-aged and older adults80 mg/d12 weeksn = 16
Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults
Hypertension (Dallas, Tex. : 1979)
Mortality
no changein humans2upin O. niloticus1
3 studies
Mortality
no changein humans2upin O. niloticus1
Atorvastatin showed no clear effect on mortality in humans (1.9% (2/107) vs 4.1% (5/123)).
“After 30 days, the all-cause mortality rate in the Ato group was 1.9% (2/107), whereas it was 4.1% (5/123) in the placebo control group, with no statistically significant difference (p =0.454, ).”
Human trial30 daysn = 230
Neuropsychiatric disease and treatment
Atorvastatin showed no clear effect on mortality in humans following surgery for malignant tumors.
“30-day all-cause mortality did not vary significantly between the two groups.”
Human trialfollowing surgery for malignant tumors40mg/day30-day
Neuropsychiatric disease and treatment
Atorvastatin was not clearly linked with mortality in humans (compared with moderate-intensity statin users, before and after propensity score matching).
“revealed no significant difference in ischaemic CCEs or all-cause mortality between the moderate-intensity statin users and 10 mg atorvastatin users”
Humanscompared with moderate-intensity statin users, before and after propensity score matching10 mgn = 4,689
Basic & clinical pharmacology & toxicology
Atorvastatin increases mortality in O. niloticus.
“The findings of this study revealed dose-dependent mortality and alterations in morphological and behavioural patterns in fish exposed to high ATV concentrations.”
Animals45 days
Research SquarePreprint
LDL-C
downin humans3−80% decrease
3 studies
LDL-C
downin humans3−80% decrease
Atorvastatin decreases LDL-C in humans (on background PCSK9 inhibitor therapy) (80% decrease).
“After 1 month of LLT, LDL-C and hsCRP decreased by 80% and 6%, respectively, in the statin group (P<0.05 for each).”
Human trialon background PCSK9 inhibitor therapy80 mg1 month
AHA Scientific Sessions 2025 abstract
Atorvastatin decreases LDL-C in humans (-40 mg/dL).
“Atorvastatin treatment reduced LDL-c by 40 mg/dL (β = −40.045; CI95% = −69.949–−10.140; p = 0.010).”
Human trial60-dayfemalesn = 39
Antioxidants (Basel, Switzerland)
Atorvastatin is linked with lower LDL-C in humans (dyslipidemia) (-54.55%).
“In 55 patients who completed follow-up, a decrease in LDL-C, total cholesterol, triglycerides, and ApoE was 54.55%, 40.60%, 53.1%, and 40.46%, respectively.”
Humansdyslipidemia12-weekn = 55
Research SquarePreprint
Rhabdomyolysis
upin humans3
3 studies
Rhabdomyolysis
upin humans3
Atorvastatin induces rhabdomyolysis in humans.
“The cause for myopathy, rhabdomyolysis, and liver injury was ascertained to be Atorvastatin”
Human trialfemales
Euroasian journal of hepato-gastroenterology
Atorvastatin induces rhabdomyolysis in humans (double prescribed dose of atorvastatin).
“She was admitted to the hospital where she was found to have rhabdomyolysis.”
Human trialdouble prescribed dose of atorvastatinfemales
Geriatrics (Basel, Switzerland)
Atorvastatin is linked with higher rhabdomyolysis in humans (single case; patient prescribed 80 mg daily after NSTEMI) (serum creatine kinase 18 723 U/L).
“Prescribing high-intensity statins for patients with advanced age, such as this case, may increase the risk of rhabdomyolysis and other complications.”
Humanssingle case; patient prescribed 80 mg daily after NSTEMI80 mg dailymales
Journal of pharmacy practice
IL-6
no changein humans1upin humans1
2 studies
IL-6
no changein humans1upin humans1
Atorvastatin increases IL-6 in humans.
“This positive atorvastatin effect on TA was associated with a statistically significant increase in IL-6 and a marginally significant decrease in blood urea.”
Human trial12 months
Frontiers in pharmacology
Atorvastatin showed no clear effect on IL-6 in humans (MD −0.82; 95% CI −3.02 to 1.38; p = 0.46).
“No overall between-group differences were observed for IL-6 (n = 484; MD –0.82; 95% CI –3.02 to 1.38; p = 0.46)”
ReviewComparison with rosuvastatin; adiponectin and TNF-α also showed no overall between-group differencesn = 484
AHA Scientific Sessions 2026 abstract
All 283Fewer
What is atorvastatin linked with?
50Studies link atorvastatin with 50 measures, among them cardiovascular disease, type 2 diabetes and postoperative delirium.
Cardiovascular disease
downin humans2HR 0.7
2 studies
Cardiovascular disease
downin humans2HR 0.7
Atorvastatin lowers the risk of cardiovascular disease in humans (without clinical cardiovascular disease) (HR 0.70, 95% CI 0.61–0.82, P<0.001).
“a primary cardiovascular event had occurred in 297 participants (10.9 events per 1000 person-years) in the atorvastatin group and in 412 participants (15.5 events per 1000 person-years) in the placebo group”
Human trialwithout clinical cardiovascular disease40 mg once daily5.9 yearsn = 9,971
Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
The New England journal of medicine
Atorvastatin lowers the risk of cardiovascular disease in humans (elderly type 2 diabetes) (-3.65% (95% CI: -10.29%, 4.38%)).
“total effect (six-year cardiovascular disease risk difference) estimated by standard plug-in g-formula of -3.65% (95% confidence interval: -10.29%, 4.38%)”
Human trialelderly type 2 diabetes6 years
Statistical methods in medical research
Type 2 diabetes
upin humans2
2 studies
Type 2 diabetes
upin humans2
Atorvastatin raises the risk of type 2 diabetes in humans (compared to agents such as pravastatin or pitavastatin).
“High-intensity statins like atorvastatin and rosuvastatin carry a greater risk compared to agents such as pravastatin or pitavastatin.”
Reviewcompared to agents such as pravastatin or pitavastatin
Statin Induced New-onset Diabetes Mellitus - A Narrative Review
Journal of community hospital internal medicine perspectives
Atorvastatin raises the risk of type 2 diabetes in humans (dose- and susceptibility-dependent).
“small dose- and susceptibility-dependent increase in new-onset diabetes”
Reviewdose- and susceptibility-dependent
Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management
Cardiovascular therapeutics
Postoperative delirium
downin humans1
1 study
Postoperative delirium
downin humans1
Atorvastatin lowers the risk of postoperative delirium in humans.
“As opposed to the Ato group, the placebo group exhibited a remarkably greater delirium occurrence rate, with a significant difference (p =0.003).”
Human trial30 daysn = 230
Neuropsychiatric disease and treatment
Atorvastatin lowers the risk of postoperative delirium in humans following surgery for malignant tumors.
“The occurrence of delirium in the Ato group was remarkably reduced unlike the case in the placebo group.”
Human trialfollowing surgery for malignant tumors40mg/day
Neuropsychiatric disease and treatment
Cardiovascular events
downin humans1
1 study
Cardiovascular events
downin humans1
Atorvastatin lowers the risk of cardiovascular events in humans.
“Multiple large trials have shown that atorvastatin achieves concurrent control of lipids and inflammation, accompanied by reductions in cardiovascular events.”
Review
Frontiers in pharmacology
Liver stiffness
downin humans1
1 study
Liver stiffness
downin humans1
Atorvastatin is associated with liver stiffness in humans (type 2 diabetes mellitus; compared with no statin) (−0.42 kPa versus −0.02 kPa in the no-statin group).
“both atorvastatin treatment groups remained significantly associated with lower six-month UACR and liver stiffness compared with the no-statin group”
Humanstype 2 diabetes mellitus; compared with no statinliver10–20 mg/daysix monthsn = 205
Medicina (Kaunas, Lithuania)
Urinary albumin-to-creatinine ratio
downin humans1
1 study
Urinary albumin-to-creatinine ratio
downin humans1
Atorvastatin is associated with urinary albumin-to-creatinine ratio in humans (type 2 diabetes mellitus; compared with no statin) (−27.68 mg/g versus +8.64 mg/g in the no-statin group).
“both atorvastatin treatment groups remained significantly associated with lower six-month UACR and liver stiffness compared with the no-statin group”
Humanstype 2 diabetes mellitus; compared with no statin10–20 mg/daysix monthsn = 205
Medicina (Kaunas, Lithuania)
Cardiovascular and cerebrovascular events
downin humans1
1 study
Cardiovascular and cerebrovascular events
downin humans1
Atorvastatin lowers the risk of cardiovascular and cerebrovascular events in humans (patients with carotid plaque; compared with no statin therapy) (22 events among 234 statin-treated patients versus 36 among 202 controls; log-rank P=0.0107).
“22 events occurred among 234 patients in the statin group and 36 among 202 patients in the control group”
Human trialpatients with carotid plaque; compared with no statin therapy20 mg dailyextended follow-up beyond 24 months through 2025
Effect of atorvastatin on carotid plaque progression-a prospective study
Frontiers in cardiovascular medicine
New-onset type 2 diabetes mellitus
downin humans1RR 0.94
1 study
New-onset type 2 diabetes mellitus
downin humans1RR 0.94
Atorvastatin is associated with new-onset type 2 diabetes mellitus in humans (stable coronary artery disease; propensity score-matched cohorts) (12.1% versus 12.8%; RR 0.94, 95% CI 0.92–0.96; HR 1.02, 95% CI 1.00–1.05; log-rank p=0.053).
“Atorvastatin 40 mg was associated with modestly lower rates of both incident HF and new-onset T2DM compared to 80 mg.”
Humansstable coronary artery disease; propensity score-matched cohorts40 mg versus 80 mg71% males
AHA Scientific Sessions 2026 abstract
Incident heart failure
downin humans1RR 0.95
1 study
Incident heart failure
downin humans1RR 0.95
Atorvastatin is associated with incident heart failure in humans (stable coronary artery disease; propensity score-matched cohorts) (19.2% versus 20.3%; RR 0.95, 95% CI 0.93–0.96; HR 1.02, 95% CI 1.01–1.04).
“Atorvastatin 40 mg was associated with modestly lower rates of both incident HF and new-onset T2DM compared to 80 mg.”
Humansstable coronary artery disease; propensity score-matched cohorts40 mg versus 80 mg71% males
AHA Scientific Sessions 2026 abstract
Circulating protein abundance
mixedin humans1
1 study
Circulating protein abundance
mixedin humans1
Atorvastatin is associated with circulating protein abundance in humans (statin-intolerant patients; placebo-controlled crossover) (243/1,037 proteins (23.4%): 140 upregulated, 103 downregulated; 57 significant after adjustment: 8 upregulated, 49 downregulated).
“atorvastatin significantly affected 243 out of 1,037 proteins (23.4%) in the unadjusted model (FDR q<0.05; 140 upregulated, 103 downregulated).”
Human trialstatin-intolerant patients; placebo-controlled crossoverplasma20 mg54% femalesn = 133
AHA Scientific Sessions 2026 abstract
Sinus arrest
upin humans1
1 study
Sinus arrest
upin humans1
Atorvastatin is associated with sinus arrest in humans following high-dose exposure.
“On admission, electrocardiography showed sinus arrest with a ventricular escape rhythm, accompanied by acute hepatic and renal dysfunction, electrolyte abnormalities, coagulation abnormalities, and elevated inflammatory markers.”
Human trialfollowing high-dose exposure80 mg dailytwo weeksmalesn = 1
Atorvastatin-Associated Severe Bradyarrhythmia Following Multiorgan Dysfunction: A Case Report
Clinical case reports
Contrast-induced acute kidney injury
downin humans1RR 1.658
1 study
Contrast-induced acute kidney injury
downin humans1RR 1.658
Atorvastatin lowers the risk of contrast-induced acute kidney injury in humans (undergoing elective coronary angiography) (12.5% vs 32.5%, RR 1.658, 95% CI 1.050-2.433).
“The incidence of CI-AKI was significantly lower in the high-dose statin group compared with the control group (risk ratio = 1.658; 95% CI 1.050-2.433).”
Human trialundergoing elective coronary angiographyoral80 mg24 h before angiographyn = 80
Clinical drug investigation
Pulmonary infection
downin humans1
1 study
Pulmonary infection
downin humans1
Atorvastatin lowers the risk of pulmonary infection in humans.
“The incidence of pulmonary infection and bedsore in the Ato group was remarkably diminished as opposed to that in the placebo group (p<0.05, ).”
Human trial30 daysn = 230
Neuropsychiatric disease and treatment
Stroke
downin humans1HR 0.9
1 study
Stroke
downin humans1HR 0.9
Atorvastatin lowers the risk of stroke in humans (recent stroke or TIA) (HR 0.90, 0.73-1.11, p = 0.33).
“and by 10% in elderly subjects (HR 0.90, 0.73-1.11, p = 0.33).”
Human trialrecent stroke or TIA
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack
Neurology
Coronary artery disease
downin humans1HR 0.68
1 study
Coronary artery disease
downin humans1HR 0.68
Atorvastatin lowers the risk of coronary artery disease in humans (recent stroke or TIA) (HR 0.68, p = 0.035).
“major coronary events (HR 0.68, p = 0.035), any coronary heart disease event (HR 0.61, p = 0.0006), and revascularization procedures (HR 0.55, p = 0.0005) was reduced in the elderly group.”
Human trialrecent stroke or TIA
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack
Neurology
All 50Fewer
Has atorvastatin been tested in people?
93 of 530 about agingYes: 75 trials and 100 observational studies in people have been published, and 521 trials are registered.
About aging
A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)
Phase 4Active, not recruiting
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Phase 4Recruiting
Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
Phase 4Active, not recruiting
Phase 4Completed
Phase 4Not yet recruiting
Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
Phase 4Completed
All 40Fewer
Approved
Dec 17, 1996Homozygous Familial Hypercholesterolemia, Hypertriglyceridemia, Myocardial Infarction, Stroke, Coronary Heart Disease, Heterozygous Familial Hypercholesterolemia, dysbetalipoproteinemia, angina, Hyperlipidemia, primary hyperlipidemia, non-fatal stroke
Feb 1, 2023Homozygous Familial Hypercholesterolemia, Hypertriglyceridemia, Myocardial Infarction, Stroke, Coronary Heart Disease, Heart Failure, Congestive, Heterozygous Familial Hypercholesterolemia, dysbetalipoproteinemia, angina, Hyperlipidemia, primary hyperlipidemia, non-fatal stroke
Repurposing
Phase 3Completed8 trials
Phase 4Results posted22 trials
Phase 3Completed3 trials
Phase 4Completed16 trials
Phase 4Completed4 trials
Phase 4Results posted17 trials
40 of 182Fewer
Every condition in trials
Hyperlipidemias
Phase 4Results posted41 trials
Variant Angina Pectoris
Phase 4Terminated3 trials
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Phase 4Status unknown2 trials
Amyloid plaque
Phase 4Status unknown1 trial
Aortic coarctation
Phase 4Terminated1 trial
Post operative atrial fibrillation
Phase 4Status unknown1 trial
All 37Fewer
Readouts due
- Dec 2026
- Dec 1, 2026
- Dec 31, 2026
- Jan 25, 2027
Phase 1Active, not recruiting
- Jan 31, 2027
- Apr 2027
All 11Fewer
Stopped
NCT02133534TerminatedHypercholesterolemia
failure to enroll
NCT02740699TerminatedCardiovascular disease
Principal Investigator resigned and closed program
NCT00355251TerminatedHIV infection
On the basis of published results of SMART study, it has been observed that the results are worse in patients who have interrupted their treatments.
NCT03228238TerminatedVariant Angina Pectoris
The study was terminated early due to slow recruitment and the Principal Investigator's retirement.
NCT00590135TerminatedAortic valve stenosis
Poor Reducibility - primary endpoint measure not obtainable
NCT05331053TerminatedEndometriosis
COVID halting human subjects research and preliminary data from this proposal were used to submit an NIH grant. The NIH grant was funded and 3 other protocols were launched.
All 16Fewer
Who is developing atorvastatin?
3 companies: Organon, Laboratorios Senosiain S.A. de C.V. and Shenzhen Salubris Pharmaceuticals.
Trial sponsors
Company29 trialsPhase 412,605 people
Company23 trialsPhase 451,867 people
Company15 trialsPhase 45,857 people
Company9 trialsPhase 4538 people
Company3 trialsPhase 498 people
Company1 trialPhase 4300 people
Company8 trialsPhase 34,155 people
Company7 trialsPhase 3536 people
Funding
1 grant since 2023National Institute on Deafness and Other Communication Disorders$1.5M
How this record changed
Summary rewritten as its findings changed.
As it read before
Atorvastatin improves cognition in mice across independent labs, although another study shows no clear effect; human trials report lower LDL cholesterol but differ on coenzyme Q10 reductions. Of its registered trials, 99 concern aging; 260 across all uses ended over a year ago without posted results or citing papers. Some trials have developer sponsors, and some papers declare Pfizer ties.
Summary rewritten as its findings changed.
As it read before
A human trial reports no improvement in disability-free survival with atorvastatin; independent labs find improved mouse cognition, while a human study finds no cognitive benefit. Independent labs also report lower human LDL cholesterol and C-reactive protein. 31 trials concern aging; 258 across all uses ended over a year ago without posted results or citing papers, and two of 54 papers declare company ties.
Summary rewritten as its findings changed.
As it read before
In humans, atorvastatin reduces plasma endoglin and endocan in females, and a preoperative trial shows it lowers cardiac troponin without affecting major adverse cardiovascular events. Reviews describe a dose-dependent increase in type 2 diabetes risk.
Summary written from the findings.